Danske Bank A S Buys 134,869 Shares of Johnson & Johnson $JNJ

Key Points

• Danske Bank increased its Johnson & Johnson stake by 6.5%, buying 134,869 shares in the third quarter to hold 2.21 million shares valued at about $585 million.
• Analysts’ consensus rating is “Moderate Buy,” with an average price target of $275.92; J&J shares recently traded at $285.78.
• J&J beat quarterly earnings estimates, reporting EPS of $2.59 and revenue of $25.40 billion. It also announced a quarterly dividend of $1.34 per share, equivalent to a 1.9% yield.

Danske Bank A S lifted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,210,087 shares of the company's stock after buying an additional 134,869 shares during the period. Johnson & Johnson comprises about 1.2% of Danske Bank A S's holdings, making the stock its 14th largest position. Danske Bank A S owned approximately 0.09% of Johnson & Johnson worth $585,098,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. CKW Financial Group raised its holdings in shares of Johnson & Johnson by 0.9% in the third quarter. CKW Financial Group now owns 4,269 shares of the company's stock valued at $1,104,000 after purchasing an additional 37 shares during the last quarter. Silver Coast Investments LLC lifted its position in shares of Johnson & Johnson by 3.8% during the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock valued at $271,000 after purchasing an additional 39 shares in the last quarter. Townsend Asset Management Corp NC ADV lifted its position in shares of Johnson & Johnson by 0.6% during the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock valued at $1,630,000 after purchasing an additional 39 shares in the last quarter. Triumph Capital Management boosted its holdings in Johnson & Johnson by 1.6% during the second quarter. Triumph Capital Management now owns 2,531 shares of the company's stock worth $643,000 after purchasing an additional 39 shares during the last quarter. Finally, Kwmg LLC boosted its holdings in Johnson & Johnson by 1.7% during the third quarter. Kwmg LLC now owns 2,383 shares of the company's stock worth $631,000 after purchasing an additional 39 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Johnson Rice lowered shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Wednesday, October 21st. UBS Group set a $270.00 target price on Johnson & Johnson in a research note on Wednesday, October 14th. TD Cowen reaffirmed a "buy" rating on shares of Johnson & Johnson in a report on Tuesday, October 20th. Royal Bank Of Canada reduced their target price on Johnson & Johnson from $290.00 to $280.00 and set an "outperform" rating for the company in a report on Wednesday, October 14th. Finally, Morgan Stanley decreased their price target on Johnson & Johnson from $294.00 to $292.00 and set an "overweight" rating for the company in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $275.92.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock traded up $2.26 during trading hours on Friday, reaching $285.78. The company had a trading volume of 6,279,519 shares, compared to its average volume of 7,472,752. The firm has a market cap of $687.95 billion, a PE ratio of 43.30, a price-to-earnings-growth ratio of 2.80 and a beta of 0.22. Johnson & Johnson has a one year low of $193.55 and a one year high of $288.11. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The business has a fifty day simple moving average of $266.97 and a 200 day simple moving average of $249.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion during the quarter, compared to analysts' expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. Johnson & Johnson's revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio (DPR) is currently 81.21%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the business's stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares of the company's stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 61,669 shares of company stock valued at $16,898,386 over the last three months. 0.16% of the stock is owned by corporate insiders.

Recent Johnson & Johnson Headlines

These are some of the JNJ headlines that stood out recently:

• Positive Sentiment: A Johnson & Johnson prostate-cancer drug combination is advancing into Phase 3, a meaningful clinical milestone that could strengthen the company’s oncology pipeline, although trial and commercial outcomes remain uncertain. Johnson & Johnson stock advances as prostate drug combo enters Phase 3
• Positive Sentiment: J&J is backing Francis Medical as it advances a water-vapor prostate-cancer treatment device toward FDA premarket approval. The investment expands its reach in minimally invasive oncology treatment. J&J leads Francis Medical investment to fund prostate cancer device
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of J&J investors. The notice provides no specific findings, but litigation-related uncertainty may weigh on sentiment. Pomerantz Law Firm Investigates Claims on Behalf of Johnson & Johnson Investors

Johnson & Johnson Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.